AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
ceftobiprole medocaril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, cefalosporanic acid derivatives | 4402 | 376653-43-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a ceftobiprole prodrug
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.50 | g | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,KIT,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TTK | 44 | |||
| kinase-selectivity-class | AXL,BRAF,CDK4,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,SYK,TEK,TGFBR1,TTK | 19 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DI01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Other cephalosporins and penems |
| FDA CS | M0003827 | Cephalosporins |
| FDA EPC | N0000175488 | Cephalosporin Antibacterial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| FDA MoA | N0000190107 | Organic Anion Transporting Polypeptide 1B1 Inhibitors |
| FDA MoA | N0000190108 | Organic Anion Transporting Polypeptide 1B3 Inhibitors |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
J01DI Other cephalosporins and penems 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.38 | acidic |
| pKa2 | 9.57 | acidic |
| pKa3 | 13.11 | acidic |
| pKa4 | 0.87 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 667MG/VIAL | ZEVTERA | ISTX | N218275 | April 3, 2024 | RX | POWDER | INTRAVENOUS | April 3, 2029 | NEW CHEMICAL ENTITY |
| 667MG/VIAL | ZEVTERA | ISTX | N218275 | April 3, 2024 | RX | POWDER | INTRAVENOUS | April 3, 2034 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| MecA | Enzyme | IC50 | 5.49 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D08885 | KEGG_DRUG |
| 4043931 | VANDF |
| 4043932 | VANDF |
| C1622308 | UMLSCUI |
| CHEBI:749953 | CHEBI |
| CHEMBL4297101 | ChEMBL_ID |
| CHEMBL1652606 | ChEMBL_ID |
| DB14733 | DRUGBANK_ID |
| C505439 | MESH_SUPPLEMENTAL_RECORD_UI |
| 252188-71-9 | SECONDARY_CAS_RN |
| 135413544 | PUBCHEM_CID |
| DB04918 | DRUGBANK_ID |
| 2691333 | RXNORM |
| 25923 | MMSL |
| 43995 | MMSL |
| d07350 | MMSL |
| 012881 | NDDF |
| 012882 | NDDF |
| 1286933007 | SNOMEDCT_US |
| 1287091002 | SNOMEDCT_US |
| 734512008 | SNOMEDCT_US |
| 734513003 | SNOMEDCT_US |
| C1100584 | UMLSCUI |
| RB6 | PDB_CHEM_ID |
| CHEMBL520642 | ChEMBL_ID |
| 209467-52-7 | SECONDARY_CAS_RN |
| 135413542 | PUBCHEM_CID |
| 10787 | IUPHAR_LIGAND_ID |
| 8531 | INN_ID |
| C443755 | MESH_SUPPLEMENTAL_RECORD_UI |
| N99027V28J | UNII |
| 5T97333YZK | UNII |
| CHEBI:140407 | CHEBI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ZEVTERA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68547-578 | INJECTION, POWDER, FOR SOLUTION | 667 mg | INTRAVENOUS | NDA | 31 sections |